Assessing infant motor development from afar: reflections on remote assessment of infant motor development

The COVID-19 pandemic accelerated a global shift from face-to-face to digital healthcare, increasing demand for valid and reliable tools that can be administered remotely. The Alberta Infant Motor Scale (AIMS) is a widely used observational measure of infant gross motor development, yet evidence supporting its psychometric performance via telehealth remains limited. This study evaluated the validity of remote AIMS administration across three digital modalities compared with traditional in-person assessment. Findings demonstrated excellent agreement between remote and face-to-face scores, confirming that virtual administration provides clinically reliable information about infant motor development. Validating the AIMS for telehealth has substantial implications for equity, research, and clinical practice. Remote delivery reduces travel, cost, and logistical barriers, improving access to early developmental assessment for families in rural, remote, or low-socioeconomic contexts. Reliable remote assessment also enables broader research participation and supports hybrid clinical models that maintain continuity of care when in-person visits are not feasible. These results strengthen confidence in digital modes of assessment and highlight remote AIMS administration as a viable, scalable approach to early developmental surveillance. The findings offer particular benefit for infants who face the greatest barriers to timely evaluation and intervention. IMPACT: Strengthens confidence in telehealth as a legitimate and scalable mode of early motor surveillance, especially for infants at risk of delay. Expands opportunities for equitable access by enabling high-quality assessment for families in rural, remote, or low-resource settings with barriers to in-person services. Supports inclusive and decentralised research models, enabling broader recruitment, reduced participant burden, and improved monitoring in clinical trials and developmental follow-up.